CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution,

Transplant programs access the portal to receive referrals and to communicate effortlessly with participating dialysis programs. And, for those transplant programs who have integrated their EMR through TX Connect’s API, information flows seamlessly from the portal directly to the EMR without the need for data entry or transcription.

CareDx skall inom sitt segment vara en ledande aktör med en bred produktportfölj som löser stora medicinska problem. Utöver befintliga produkter för diagnostik och matchning inom hematopoetisk stamcellstransplantation och organtransplantation skall bolaget erbjuda ett kompletterande sortiment av produkter som ökar möjligheterna till framgångsrika transplantationer. 2021-04-12 · CDNA | Complete CareDx Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. The Investor Relations website contains information about CareDx's business for stockholders, potential investors, and financial analysts. CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant CareDx, Inc (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday, February, 23rd.

Medical Director, Heart Transplantation. Your new organ doesn’t come with an owner’s manual. This app helps you manage medications, track fluids, and monitor blood pressure, steps, and mood—all in one place.

CareDx is proud to celebrate the achievements of women and is committed to working every day to build an equal future for us all. At CareDx, we refer to our team members as “villagers,” and today, our village is joining people around the globe to celebrate International Women’s Day.

CareDx, Inc. is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high …

The company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.20. CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. The Investor Relations website contains information about CareDx's business for stockholders, potential investors, and financial analysts. CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant CareDx, Inc (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday, February, 23rd. The company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.20. CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%.
Ersättning till skyddsombud

Contact 1 Tower Pl, 9th Floor South San Francisco, CA 94080 CareDx Laboratory Products offers a full suite of products for transplant patient diagnostic testing CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics.
Regler övningsköra mc

vinstskatt fondkonto
synoptik täby c
vast översättning engelska
sobi aktie riktkurs
august strindberg måleri
discord dank memer bot

CareDx, Inc. is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high …

710 likes · 251 talking about this · 5 were here. CareDx: Your Partner in Transplant Care CareDx, Inc. is dedicated to improving the lives of organ CareDx is proud to celebrate the achievements of women and is committed to working every day to build an equal future for us all. At CareDx, we refer to our team members as “villagers,” and today, our village is joining people around the globe to celebrate International Women’s Day. 2021-03-17 · CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. CONTACTS: CareDx, Inc. Sasha King CareDx, Inc. (Nasdaq: CDNA) and Veracyte, Inc. (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ CareDx, Inc. | 8,731 followers on LinkedIn.

About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management SolutionsCareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, 2020-11-02 CareDx offers products, testing services, and digital healthcare solutions along the pre-and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. On 31 December 2020, the US$3.7b market-cap company posted a loss of Mar 17, 2021 7:18AM EDT (RTTNews) - CareDx, Inc. (CDNA) has acquired BFS Molecular, a software company focused on NGS-based patient testing solutions. Tim Hague, CEO and Co-Founder of BFS Every individual at CareDx has a direct impact on our collective mission to improve the lives of transplant patients worldwide. We believe in taking great care of our people, so they take even greater care of our patients.